Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Design and application of HSV vectors for neuroprotection.

Literature DB >> 10673716

Design and application of HSV vectors for neuroprotection.

D J Fink¹, N A DeLuca, M Yamada, D P Wolfe, J C Glorioso.

Abstract

Herpes simplex virus has been extensively genetically modified for gene transfer to nerve and other tissues, to create vectors that are devoid of viral gene expression and toxicity. Recombinant vectors have been engineered to express genes which protect neurons against toxic insults resulting in cell death, including nerve growth factor (NGF) and anti-apoptotic genes (eg bcl-2). This review describes experiments using HSV vectors expressing these gene products and their potential protective role in ameliorating neurodegenerative processes in animal model systems.

Entities: Disease Gene

Mesh：

Substances：

Year: 2000 PMID： 10673716 DOI： 10.1038/sj.gt.3301118

Source DB: PubMed Journal: Gene Ther ISSN： 0969-7128 Impact factor: 5.250

Keyword Cloud
Cited

6 in total

1. Dual-gene, dual-cell type therapy against an excitotoxic insult by bolstering neuroenergetics.

Authors: Tonya M Bliss; Miranda Ip; Elise Cheng; Masabumi Minami; Luc Pellerin; Pierre Magistretti; Robert M Sapolsky
Journal: J Neurosci Date: 2004-07-07 Impact factor: 6.167

2. An M2 Rather than a T_H2 Response Contributes to Better Protection against Latency Reactivation following Ocular Infection of Naive Mice with a Recombinant Herpes Simplex Virus 1 Expressing Murine Interleukin-4.

Authors: Dhong Hyun Lee; Homayon Ghiasi
Journal: J Virol Date: 2018-04-27 Impact factor: 5.103

Design and application of HSV vectors for neuroprotection.

1. Dual-gene, dual-cell type therapy against an excitotoxic insult by bolstering neuroenergetics.

2. An M2 Rather than a T_H2 Response Contributes to Better Protection against Latency Reactivation following Ocular Infection of Naive Mice with a Recombinant Herpes Simplex Virus 1 Expressing Murine Interleukin-4.

3. Gene therapy for bladder overactivity and nociception with herpes simplex virus vectors expressing preproenkephalin.

Review 4. Gene therapy for the treatment of diabetic neuropathy.

5. Effects of herpes simplex virus vector-mediated enkephalin gene therapy on bladder overactivity and nociception.

Review 6. Targeted drug delivery to the peripheral nervous system using gene therapy.

Design and application of HSV vectors for neuroprotection.

1. Dual-gene, dual-cell type therapy against an excitotoxic insult by bolstering neuroenergetics.

2. An M2 Rather than a TH2 Response Contributes to Better Protection against Latency Reactivation following Ocular Infection of Naive Mice with a Recombinant Herpes Simplex Virus 1 Expressing Murine Interleukin-4.

3. Gene therapy for bladder overactivity and nociception with herpes simplex virus vectors expressing preproenkephalin.

Review 4. Gene therapy for the treatment of diabetic neuropathy.

5. Effects of herpes simplex virus vector-mediated enkephalin gene therapy on bladder overactivity and nociception.

Review 6. Targeted drug delivery to the peripheral nervous system using gene therapy.

2. An M2 Rather than a T_H2 Response Contributes to Better Protection against Latency Reactivation following Ocular Infection of Naive Mice with a Recombinant Herpes Simplex Virus 1 Expressing Murine Interleukin-4.